Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 11/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30035345 | 1.00 | MAP2K1 (0.48) | MAP2K1MAP2K2IDO1FLT1HDAC3 | |
| SCHEMBL24349740 | 0.89 | MEN1 (0.40) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL30035117 | 0.88 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1FLT1 | |
| SCHEMBL20565254 | 0.88 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1FLT1 | |
| SCHEMBL29536816 | 0.88 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1FLT1 | |
| SCHEMBL20565252 | 0.86 | MAP2K1 (0.48) | MAP2K1MAP2K2IDO1HDAC3HDAC1 | |
| SCHEMBL20565738 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL30034159 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL20564882 | 0.81 | MAP2K1 (0.49) | MAP2K1MAP2K2IDO1FLT1HDAC3 | |
| SCHEMBL30035019 | 0.81 | MAP2K1 (0.49) | MAP2K1MAP2K2IDO1FLT1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-3883554-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883553-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| CN-111093658-A | Fused heteroaromatic-aniline compounds for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3624795-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFlection Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213807-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885IDO1 623/4885 |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885IDO1 370/4885 |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885IDO1 370/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885IDO1 373/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MAP2K1 3307/4885MAP2K2 3471/4885IDO1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.